102767-28-2 | Levetiracetam

Chemical type

• Antiseizure medication (ASM) and P-gp substrate

^[1]

• Antiseizure medication (ASM)

^[2]

Key properties

• Transported by P-gp, contributing to drug-resistance
• Brain concentrations increased via P-gp inhibition

^[1]

• Enters saliva by passive diffusion
• Reflects free unbound fraction in plasma
• Higher salivary concentrations associated with adverse events
• Lower plasma levels and dosages associated with seizure freedom (salivary levels show indirect association after adjustment)
• Variable correlation between saliva and plasma levels (R² = 0.59)
• Short half-life leading to fluctuations in salivary concentrations

^[2]

• Treatment of drug-resistant epilepsy
• Evaluated in PET and animal studies with P-gp modulators

^[1]

• Treatment of epilepsy to achieve seizure freedom
• Monotherapy or add-on therapy in polytherapy regimens
• Therapeutic drug monitoring (TDM) for tolerability and adverse event management

^[2]

Classification by use

• Chemicals used as antiseizure medications
• P-gp substrates in epilepsy research

^[1]

• Antiepileptic drugs
• Chemicals used in neurological disorder management

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Tolerability of tariquidar – A third generation P-gp inhibitor as add-on medication to antiseizure medications in drug-resistant epilepsy, Seizure: European Journal of Epilepsy, Volume 119, July 2024, Pages 44-51
2. [Cite:2] Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?, Epilepsy & Behavior, Volume 171, October 2025, 110595